Trial Profile
An Open-label, Single-dose Study to Investigate the Pharmacokinetics and Safety of TMC278 After Oral Administration of TMC278 25 mg Tablet Under Fed Condition in Healthy Japanese Adult Male Subjects
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 May 2013
Price :
$35
*
At a glance
- Drugs Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Janssen Pharmaceutical KK
- 31 Mar 2013 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 08 Mar 2013 New trial record